ClinicalTrials.gg

Program

cenvacibart

Also written as “REGN7508”, “Cenvacibart” and “REGN7508 (IV)”.

Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Venous Thrombosis · Stroke · Kidney Failure, Chronic, led by Regeneron Pharmaceuticals.

Furthest: phase 3, since Jun 3, 202515 company-led studies, 11 open or runningNext primary completion: Feb 9, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals1511 open or runningphase 3since Jun 3, 2025Oct 27, 2022Feb 9, 2027phase 2 · NCT07175428

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2022First study: phase 1 study in Healthy VolunteerFirst studyNCT05603195 · 80 enrolled · United Kingdom
  2. Mar 1, 2024Phase 2 study in Venous ThromboembolismNCT06299111 · 195 enrolled · United States, Bulgaria, Canada and more
  3. May 30, 2024Phase 1 study in HemorrhageNCT06444178 · 224 enrolled · United Kingdom
  4. Jun 6, 2024Phase 2 study in Venous ThromboembolismNCT06454630 · 179 enrolled · Bulgaria, Hungary, Latvia and more
  5. Jun 3, 2025Phase 3 study in Venous ThromboembolismNCT07015905 · 2,000 planned · United States, Bulgaria, Hungary and more
  6. Sep 9, 2025Phase 2 study in Atrial FibrillationNCT07175428 · 1,200 planned · United States, Argentina, Brazil and more
  7. Oct 3, 2025Phase 3 study in Venous ThrombosisNCT07213778 · 2,000 planned · United States, Greece, Malaysia and more
  8. Feb 6, 20262 phase 3 studiesNCT07410117, NCT07430956
  9. Mar 5, 2026Phase 3 study in Venous ThromboembolismNCT07493304 · 1,600 planned · United States, Bulgaria, Japan and more
  10. May 29, 2026Phase 3 study in Atrial FibrillationNCT07626411 · 15,364 planned · United States, Canada, Japan
  11. Jul 6, 2026Phase 3 study in Venous ThromboembolismNCT07697599 · 1,908 planned · Georgia
  12. Aug 6, 2026Phase 1 study in Kidney Failure, ChronicNCT07759167 · 36 planned · Belgium
  13. Oct 9, 2026Phase 1 study in Healthy VolunteersNCT07876505 · 80 planned
  14. Oct 9, 2026Phase 3 study in StrokeNCT07876492 · 6,106 planned

Ahead

  1. Feb 9, 2027Primary completion: phase 2 study in Atrial FibrillationNCT07175428
  2. Feb 20, 2027Primary completion: phase 3 study in Venous ThromboembolismNCT07015905
  3. Mar 23, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07876505
  4. Apr 2, 2027Primary completion: phase 1 study in Kidney Failure, ChronicNCT07759167

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07876505Healthy Volunteers1Not yet recruitingMar 23, 202780
NCT07876492Stroke3Not yet recruitingDec 15, 20296,106
NCT07759167Kidney Failure, Chronic · Belgium1RecruitingApr 2, 202736
NCT07697599Venous Thromboembolism · Georgia3RecruitingJun 25, 20291,908
NCT07626411Atrial Fibrillation · United States, Canada, Japan3RecruitingSep 11, 202915,364
NCT07493304Venous Thromboembolism · United States, Bulgaria, Japan and more3RecruitingJul 18, 20311,600
NCT07430956Atrial Fibrillation · United States, Canada3RecruitingMar 28, 20292,628
NCT07410117Venous Thromboembolism · United States, Georgia, Japan3RecruitingJan 23, 20301,120
NCT07213778Venous Thrombosis · United States, Greece, Malaysia and more3RecruitingMay 17, 20272,000
NCT07175428Atrial Fibrillation · United States, Argentina, Brazil and more2RecruitingFeb 9, 20271,200
NCT07015905Venous Thromboembolism · United States, Bulgaria, Hungary and more3RecruitingFeb 20, 20272,000
NCT06454630Venous Thromboembolism · Bulgaria, Hungary, Latvia and more2CompletedNov 19, 2024179
NCT06444178Hemorrhage · United Kingdom1CompletedApr 7, 2025224
NCT06299111Venous Thromboembolism · United States, Bulgaria, Canada and more2CompletedMar 27, 2026195
NCT05603195Healthy Volunteer · United Kingdom1CompletedSep 17, 202480

How it is read

Names in the registry

  • “REGN7508”, 12 entries
  • “Cenvacibart”, 2 entries
  • “REGN7508 (IV)”, 1 entry
  • “REGN7508 (SC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.